for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptive Biotechnologies Corp

ADPT.O

Latest Trade

33.62USD

Change

0.71(+2.16%)

Volume

3,325,844

Today's Range

31.72

 - 

34.70

52 Week Range

30.41

 - 

71.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
32.91
Open
33.29
Volume
3,325,844
3M AVG Volume
23.11
Today's High
34.70
Today's Low
31.72
52 Week High
71.25
52 Week Low
30.41
Shares Out (MIL)
140.31
Market Cap (MIL)
4,617.64
Forward P/E
-19.92
Dividend (Yield %)
--

Next Event

Adaptive Biotechnologies Corp Annual Shareholders Meeting

Latest Developments

More

Adaptive Biotechnologies Reports Q1 2021 Financial Results

Adaptive Biotechnologies - Comments On Genentech Collaboration To Develop Of Cellular Therapy Drugs For Treating Cancer

Adaptive Biotechnologies Reports Q4 And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Industry

Business Services

Contact Info

1551 Eastlake Ave E Ste 200

SEATTLE, WA

98102-7402

United States

+1.206.6590067

https://www.adaptivebiotech.com

Executive Leadership

Chad M. Robins

Executive Chairman, Chief Executive Officer, Co-Founder

Julie Rubinstein

President

Harlan S. Robins

Co-Founder, Chief Scientific Officer

Chad M. Cohen

Chief Financial Officer

Mark R. Adams

Chief Operating Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.1K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2019

-1.010

2020

-1.110

2021(E)

-1.652
Price To Earnings (TTM)
--
Price To Sales (TTM)
39.84
Price To Book (MRQ)
6.34
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-17.65
Return on Equity (TTM)
-15.97

Latest News

Latest News

BRIEF-Adaptive Biotechnologies Posts Quarterly Loss Per Share $0.25

* ADAPTIVE BIOTECHNOLOGIES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

* AMGEN AND ADAPTIVE BIOTECHNOLOGIES ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP A THERAPEUTIC TO PREVENT OR TREAT COVID-19

BRIEF-Adaptive Biotechnologies And Microsoft Expand Partnership To Decode Covid-19 Immune Response And Provide Open Data Access

* ADAPTIVE BIOTECHNOLOGIES AND MICROSOFT EXPAND PARTNERSHIP TO DECODE COVID-19 IMMUNE RESPONSE AND PROVIDE OPEN DATA ACCESS

BRIEF-Adaptive Posts 41% Increase In Q4 Revenue

* ADAPTIVE BIOTECHNOLOGIES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

BRIEF-Adaptive, Genentech Partner To Use Clonoseq Assay In Study Of Chronic Lymphocytic Leukemia Patients

* ADAPTIVE AND GENENTECH PARTNER TO USE CLONOSEQ ASSAY TO MEASURE MINIMAL RESIDUAL DISEASE AS A PRIMARY ENDPOINT IN PHASE III STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up